Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte quality is determined based on its nuclear maturation and the presence of specific cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists) are used during controlled ovarian stimulation (COS) protocols in order to prevent premature luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type of GnRH analogues used during COS could affect the oocyte morphology, especially with the limited and conflicted currently available data. Thus, we are conducting this prospective, non-randomised, open-label, clinical trial to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on oocyte morphology during IVF/ICSI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damascus University
• Treatments: Cetrorelix; Chorionic Gonadotropin; Menotropins; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Women undergoing IVF/ICSI.

• Age: 18-39 years.

• Both ovaries present.

Exclusion Criteria:

• Age ≥ 40 years

• History of three or more previous IVF failures.

• Patients with hormonal disorders like hyperprolactinemia, thyroid disorders.

• Patients with Polycystic Ovarian Syndrome.

• Patients who previously undergo Unilateral Oophorectomy.

• Patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver diseases, kidney diseases.

• Patients with diseases may affect IVF outcomes: Endometriosis, uterine fibroids, Hydrosalpinx, Adenomyosis, autoimmune diseases,

• Cancer.